{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:33:51Z","timestamp":1786991631270,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jcehepatology.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jceh.2024.101367","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T11:40:13Z","timestamp":1709206813000},"page":"101367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Fixed Dose Combination of Sofosbuvir and Velpatasvir is Safe and Effective in Patients of Chronic Hepatitis C With End-stage Renal Disease"],"prefix":"10.1016","volume":"14","author":[{"given":"Manas K.","family":"Behera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9576-4745","authenticated-orcid":false,"given":"Prabir","family":"Majji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanatan","family":"Behera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Pani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6796-9240","authenticated-orcid":false,"given":"Arupam","family":"Mohapatro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh C.","family":"Patra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanta K.","family":"Jena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2024.101367_bib1","doi-asserted-by":"crossref","first-page":"892","DOI":"10.7150\/ijms.43079","article-title":"Direct-acting antiviral in the treatment of chronic hepatitis C: bonuses and challenges","volume":"17","author":"Zeng","year":"2020","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.jceh.2024.101367_bib2","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/hep.30303","article-title":"Impact of all-oral direct-acting antivirals on clinical and economic outcomes in patients with\u00a0chronic hepatitis C in the United States","volume":"69","author":"Park","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2024.101367_bib3","first-page":"214","article-title":"Hepatitis C virus and\u00a0liver transplantation","volume":"13","author":"Bhamidimarri","year":"2017","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2024.101367_bib4","first-page":"224","article-title":"Tackling the hepatitis C disease burden in Punjab, India","volume":"6","author":"Dhiman","year":"2016","journal-title":"J\u00a0ClinExpHepatol"},{"key":"10.1016\/j.jceh.2024.101367_bib5","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1007\/s10620-005-9025-9","article-title":"Distribution of HCV genotypes in patients with end-stage renal disease according to type of dialysis treatment","volume":"51","author":"Selcuk","year":"2006","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jceh.2024.101367_bib6","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jceh.2014.05.006","article-title":"Consensus statement of HCV task force of the Indian national association for study of the liver (INASL). Part I: status report of HCV infection in India","volume":"4","author":"Puri","year":"2014","journal-title":"J\u00a0ClinExp Hepatol"},{"key":"10.1016\/j.jceh.2024.101367_bib7","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/TP.0b013e3181f92548","article-title":"Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand","volume":"90","author":"Scott","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.jceh.2024.101367_bib8","first-page":"189","article-title":"Sofosbuvir-velpatasvir fixed drug combination for the treatment of chronic hepatitis C infection in patients with end-stage renal disease and kidney transplantation","volume":"10","author":"Gaur","year":"2020","journal-title":"J\u00a0ClinExpHepatol"},{"key":"10.1016\/j.jceh.2024.101367_bib9","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1053\/ajkd.2001.28576","article-title":"Hepatitis C virus infection and renal transplantation","volume":"38","author":"Fabrizi","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jceh.2024.101367_bib10","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40264-016-0420-2","article-title":"Pharmacokinetics, efficacy, and safety of hepatitis C virus drugs in patients with liver and\/or renal impairment","volume":"39","author":"Smolders","year":"2016","journal-title":"Drug Saf"},{"key":"10.1016\/j.jceh.2024.101367_bib11","series-title":"Recommendations for Testing, Managing, and Treating Hepatitis C-The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America","year":"2018"},{"key":"10.1016\/j.jceh.2024.101367_bib12","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1007\/s10620-018-4979-6","article-title":"Low-dose sofosbuvir is safe and effective in treating chronic hepatitis C in patients with severe renal impairment or end-stage renal disease","volume":"63","author":"Taneja","year":"2018","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jceh.2024.101367_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hep.27366","article-title":"Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus","volume":"61","author":"Yoshida","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2024.101367_bib14","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jhep.2019.11.014","article-title":"Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals","volume":"72","author":"Liu","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2024.101367_bib15","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/liv.14320","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in renally impaired patients with chronic HCV infection","volume":"40","author":"Lawitz","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2024.101367_bib16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/MEG.0000000000001923","article-title":"Hepatitis C therapy with grazoprevir\/elbasvir and glecaprevir\/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R)","volume":"34","author":"Stein","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2024.101367_bib17","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/liv.14299","article-title":"Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment","volume":"40","author":"Eletreby","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2024.101367_bib18","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jceh.2024.101367_bib19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2017.03.047","article-title":"Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials","volume":"153","author":"Jacobson","year":"2017","journal-title":"Gastroneterology"},{"key":"10.1016\/j.jceh.2024.101367_bib20","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jceh.2024.101367_bib21","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jhep.2019.05.028","article-title":"Sofosbuvir\/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis","volume":"71","author":"Borgia","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2024.101367_bib22","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/apt.16830","article-title":"Sofosbuvir and risk of estimated glomerular filtration rate decline or end-stage renal disease in patients with renal impairment","volume":"55","author":"Sulkowski","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2024.101367_bib23","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.cgh.2021.07.037","article-title":"Impact of sofosbuvir-based direct-acting antivirals on renal function in chronic hepatitis C patients with impaired renal function: a large cohort study from the nationwide HCV registry program (TACR)","volume":"20","author":"Huang","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2024.101367_bib24","first-page":"189","article-title":"Sofosbuvir-velpatasvir fixed drug combination for the treatment of chronic hepatitis C infection in patients with end-stage renal disease and kidney transplantation","volume":"10","author":"Gaur","year":"2020","journal-title":"J\u00a0ClinExpHepatol"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688324000240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688324000240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:56:45Z","timestamp":1719622605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688324000240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0973688324000240"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2024.101367","relation":{},"ISSN":["0973-6883"],"issn-type":[{"value":"0973-6883","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Fixed Dose Combination of Sofosbuvir and Velpatasvir is Safe and Effective in Patients of Chronic Hepatitis C With End-stage Renal Disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2024.101367","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101367"}}